Get the Stockscreener App
821.91
1.32%
-11.58
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $821.91, with a volume of 1.26M.
It is down -1.32% in the last 24 hours and up +8.88% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$833.49
Open:
$832.68
24h Volume:
1.26M
Relative Volume:
0.28
Market Cap:
$777.89B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
54.50
EPS:
15.0808
Net Cash Flow:
$-50.20M
1W Performance:
-2.67%
1M Performance:
+8.88%
6M Performance:
+12.29%
1Y Performance:
-11.76%
1-Day Range:
$820.30
$835.32
1-Week Range:
$820.30
$864.35
52-Week Range:
$623.78
$937.00
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
821.90 | 747.19B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.43 | 459.32B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
231.57 | 407.19B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
129.74 | 251.72B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
85.61 | 214.78B | 63.43B | 16.42B | 14.72B | 6.4861 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Eli Lilly: The Rally Has More Room To Run (Rating Upgrade) (NYSE:LLY) - Seeking Alpha
Down 44%, Should You Buy the Dip on Viking Therapeutics? - The Motley Fool
Precision Trading with Eli Lilly And Company (LLY) Risk Zones - news.stocktradersdaily.com
Eli Lilly Omvoh Demonstrates Sustained Long-Term Benefits in Ulcerative Colitis Up to Four Years - Yahoo Finance
Eli Lilly (NYSE: LLY) Stock Price Prediction and Forecast 2025-2030 (Oct 2025) - 24/7 Wall St.
Eli Lilly Opens R&D Incubator for Life Sciences Startups - San Diego Business Journal
Aspen wins approval to market Lilly's Mounjaro for weight loss in South Africa - Reuters
Should Omvoh’s Clinical Success and Earnings Optimism Prompt Action from Eli Lilly (LLY) Investors? - simplywall.st
Should Omvoh’s Clinical Results and Innovation Drive a Rethink of Eli Lilly’s (LLY) Specialty Focus? - Yahoo Finance
The Goldman Sachs Group Issues Positive Forecast for Eli Lilly and Company (NYSE:LLY) Stock Price - MarketBeat
Insider Sales Surge: Block, Eli Lilly, Strategy, P&G, Dell - TipRanks
Eli Lilly and Company (NYSE:LLY) Stock Unloaded Rep. Val T. Hoyle - MarketBeat
Should Investors Buy Eli Lilly Stock? - The Globe and Mail
Meet this year’s Women in Biopharma; Peter Marks goes to Eli Lilly; Bob Langer startup launches; and more - Endpoints News
Gunderson Capital Management Inc. Increases Position in Eli Lilly and Company $LLY - MarketBeat
Seeking Safe Havens: Why Pfizer and Eli Lilly Are Top Market Picks Now? - NAI500
Major Shareholder Sells Millions in Eli Lilly Stock! - TipRanks
Eli Lilly (LLY): Revisiting Valuation After Recent Share Price Gains - simplywall.st
Lilly Endowment sells Eli Lilly shares worth $9.04 million - Investing.com
Eli Lilly and Co(LLY.US) 10% Shareholder Sells US$9.04 Million in Common Stock - 富途牛牛
Lilly Endowment unloads about $600 million in Eli Lilly stock during early October - Sherwood News
Eli Lilly’s New Study on Weight Reduction Drugs: A Potential Market Game-Changer? - TipRanks
Next medicine deal after Pfizer? Analysts, shares point to AstraZeneca, Eli Lilly - Reuters
Next Medicine Deal After Pfizer? Analysts, Shares Point to AstraZeneca, Eli Lilly - Money US News.com
WHO Arm Seeks Talks with Novo Nordisk, Eli Lilly on Expanding Access to Weight-loss Drugs - MarketScreener
Shape’s former CSO picks up tech role at Moderna; Lilly reels in Peter Marks - Endpoints News
2 Pharmaceutical Stocks That Look Like No-Brainer Buys Right Now - The Globe and Mail
Verde Servicos Internacionais S.A. Purchases New Position in Eli Lilly and Company $LLY - MarketBeat
Baxter Bros Inc. Lowers Stock Position in Eli Lilly and Company $LLY - MarketBeat
Major Shareholder Cashes Out Millions in Eli Lilly Stock! - TipRanks
LILLY ENDOWMENT INC Reduces Stake in Eli Lilly and Co - GuruFocus
Eli Lilly (LLY) Gains As Market Dips: What You Should Know - Yahoo Finance
Lilly Endowment sells Eli Lilly & Co (LLY) shares for $86.2m - Investing.com Canada
A Major Eli Lilly Shareholder Has Sold Stock Nearly Every Day in October. Here’s Who It Is. - MSN
Eli Lilly Completes Phase 1 Study for Bimagrumab and Tirzepatide Amidst Strategic Pipeline Revisions - FinancialContent
Lobbying Update: $10,000 of ELI LILLY & COMPANY lobbying was just disclosed - Quiver Quantitative
Eli Lilly Completes Phase 1 Study on Bimagrumab and Tirzepatide: Market Implications - TipRanks
US-based Eli Lilly to invest $1 billion in India - The Indian EYE
AbbVie vs. Eli Lilly: Which Large Drugmaker Has the Edge in 2025? - Yahoo Finance
Eli Lilly and Company ($LLY) Stock: Appoints Former FDA Biologics Head Peter Marks as Senior VP of Molecule Discovery - CoinCentral
Watch Out Eli Lilly, This Pharma Giant Is Gunning to Be a Top Player in the Obesity Market - Yahoo Finance
Cantor Fitzgerald Adjusts PT on Eli Lilly and Co. to $925 From $825, Maintains Overweight Rating - MarketScreener
Notis McConarty Edward Acquires 1,424 Shares of Eli Lilly and Company $LLY - MarketBeat
Capital Management Associates Inc Cuts Stock Position in Eli Lilly and Company $LLY - MarketBeat
Dempze Nancy E Increases Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Richmond United to vacate West Creek soccer complex, make way for $5B Eli Lilly pharma facility - Richmond BizSense
Eli Lilly To Invest $1 Billion In India, Boosts Hyderabad’s Pharma Sector - indica News
US pharma company: Eli Lilly to invest USD 1 billion in India; Piyush Goyal reacts - ET Now
Major Shareholder Cashes In on Eli Lilly & Co Stock! - TipRanks
Eli Lilly’s SWOT analysis: stock poised for growth amid obesity market boom - Investing.com
Judge Drops Eli Lilly’s Suit Over Compounded Zepbound, Mounjaro - Bloomberg Law News
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.13%
0.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):